Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated with Targeted Therapy

Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated with Targeted Therapy: the Model of Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors.

French prospective multicenter, open-label study involving newly diagnosed CML patients. Two assessments will be performed during the follow-up of these patients: individual frailty using geriatric tools and individual biological aging determined by DNA methylation analysis.

Inclusion Criteria:

• Age ≥18 years
• CML in chronic phase at time of diagnosis. Diagnosis must be made no more than 3 months (90 days) prior to inclusion. Diagnosis of chronic-phase CML (European Leukemia Network [ELN] 2020 criteria; Baccarani et al 2013) with confirmation of a Philadelphia chromosome (Ph1). A cryptic Ph1 chromosome must be confirmed by FISH.Criteria must meet the definition of chronic phase CML
• BCR ::ABL1 transcript quantifiable by quantitative PCR
• 1st-line treatment with tyrosine kinase inhibitor
• No tyrosine kinase inhibitor or hydroxyurea treatment received prior to first blood sampling (at diagnosis)
• Signature of informed consent for CML Observatory and signature of informed consent for BIO-TIMER protocol
• Read and understand French
• Enrolled in a social security plan or beneficiary of such a plan

Exclusion Criteria:

• CML in accelerated or blast phase
• Refusal to participate in the study
• Treatment started prior to inclusion
• Patients under guardianship, curatorship, deprivation of liberty or safeguard of justice
• Pregnant or breast-feeding women